What Diamicron LM Treats: Main Uses and Benefits

Diamicron LM is commonly used to provide supportive therapeutic benefit in adults with Type 2 Diabetes Mellitus. It is applied to help manage and reduce high blood sugar levels (hyperglycemia), which are symptoms related to systemic imbalance that may create noticeable physiological strain. This medication is used within therapeutic domains involving significant symptom expression associated with the condition.

The therapeutic application helps address symptom clusters that may become intense or disruptive and is relevant for managing conditions characterized by periods of heightened symptoms. It is used across domains where additional symptomatic support is needed, assisting with maintaining functional stability and contributing to easing the overall symptom load. This medication is applied across domains where additional symptomatic support is needed.

“This medication is considered relevant when supportive symptom management is appropriate for fluctuating blood sugar, may assist with maintaining functional stability during symptom fluctuations.”

Quick Fact: Support for Systemic Imbalance

Commonly used across conditions presenting with acute episodes, Diamicron LM is applied in scenarios where additional management of discomfort is required, providing supportive relief when symptoms interfere with routine activities.

Diamicron LM (Gliclazide Modified-Release) is officially indicated for adults with Type 2 Diabetes Mellitus when diet and exercise alone are insufficient. Use in older adults (ge 65 years) is generally approved using the same adult regimen.

The medicine is absolutely contraindicated (must not be used) in several populations as defined by regulatory bodies:

• Diabetes Type: Individuals with Type 1 Diabetes Mellitus or those in a state of diabetic keto-acidosis or diabetic pre-coma.
• Organ Function: Patients with severe hepatic insufficiency or severe renal insufficiency.
• Hypersensitivity: Those with a known allergy to gliclazide, other sulfonylureas, or related sulfonamides.

---

Eligibility Restrictions

Population Group	Official Regulatory Status
Pregnancy	Not Recommended/Contraindicated (must switch to insulin).
Lactation	Contraindicated (risk of neonatal hypoglycemia).
Pediatric Use (lt 18 years)	Not Recommended (safety and efficacy not established).
Stress Conditions	May require temporary discontinuation and substitution with insulin (e.g., severe infection, surgery).

For patients with mild to moderate renal impairment, the medicine may be used with careful patient monitoring.

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Diamicron LM (Gliclazide), based strictly on regulatory prescribing information. The combination of Gliclazide with Miconazole (systemic or oromucosal gel) is contraindicated due to the potentiation of the hypoglycaemic effect, which carries a risk of coma.

---

Documented Interaction Classes

The interaction profile is divided into agents that potentiate the glucose-lowering effect (increasing risk of low blood sugar) and those that attenuate it (increasing risk of high blood sugar).

• Potentiation of Effect: Substances that increase the action of Gliclazide include other antidiabetic agents, Beta-blockers, ACE Inhibitors, MAO Inhibitors, and Phenylbutazone (which reduces drug elimination and displaces protein binding). Alcohol is also documented to potentiate the hypoglycaemic action and must be avoided.
• Attenuation of Effect: Substances that may increase blood glucose levels include Danazol, Chlorpromazine, Glucocorticoids, and Beta-2 Sympathomimetics (e.g., Ritodrine, Salbutamol). Preparations containing St. John's Wort are documented to decrease Gliclazide exposure.

---

Specific Cautions

The risk of severe hypoglycaemic reactions is officially noted as increased in patients with Severe Renal or Hepatic Insufficiency. Furthermore, the administration requires a regular food intake (including breakfast), as irregular intake increases the risk of hypoglycemia.

Selective Blockade of Pancreatic Ion Channels

The primary mechanism of Gliclazide is the high-affinity binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the beta-cell's ATP-sensitive potassium channel ( K ATP channel). This molecular interaction causes the channel to close, stopping the outward flow of potassium ions ( K^+) from the cell. This targeted action initiates the chain of molecular events that leads to hormone release.

---

The Ca^2+-Mediated Cellular Secretion Cascade

The inhibition of the K ATP channel causes the beta-cell membrane to undergo depolarization. This change in potential opens voltage-dependent calcium channels, resulting in a rapid surge of calcium ions ( Ca^2+) into the cell. This increase in intracellular calcium is the final trigger that prompts the exocytosis (release) of stored insulin into the bloodstream.

---

Modulation of Systemic Glucose Flux

The resulting elevation in circulating insulin levels generates two major physiological consequences: it suppresses the production and release of new glucose by the liver (hepatic glucose output) and simultaneously promotes the efficient uptake of glucose by peripheral tissues like muscle and fat. This combined systemic modulation results in a reduction of the glucose concentration in the bloodstream.

How to Use Diamicron LM

The administration of Diamicron LM (Gliclazide modified-release) is governed by specific instructions to ensure the proper oral intake of the medicine. The dosage regimen is highly standardized and follows a prescribed, stepwise titration process.

---

Official Dosing and Scheduling

Instruction	Detail
Route of Administration	Oral intake of the modified-release tablet.
Dosing Schedule (Adults)	Starting Dose: 30 mg daily. Maintenance: 30 mg to 120 mg daily. Maximum Dose: 120 mg daily.
Frequency	Must be taken as a single daily intake.
Timing & Food	Take the dose at breakfast time and ensure the administration is tied to regular food intake.

---

Administration Requirements and Adjustments

Tablet Handling and Intake

The modified-release tablet must be swallowed whole with a glass of water; it should not be crushed or chewed. The 60 mg tablet is scored and can be divided into two equal halves to facilitate the 30 mg starting dose.

Dose Adjustment (Titration)

Increases in dosage, if necessary, are typically made in steps of 30 mg. The interval between dose adjustments should generally be at least one month. If blood glucose levels are not adequately controlled, the dose may be increased after a minimum of two weeks of treatment.

Missed Dose Rules

If a dose is forgotten, the patient must not increase the dose taken the next day; the next dose should be taken at the usual time.

Specific Populations

• Older Adults (≥ 65 years): The dosage regimen is identical to that recommended for younger adults, beginning at 30 mg daily.
• Renal Impairment: No dosage adjustment is required for patients with mild to moderate renal insufficiency.
• Pediatric Population: The safety and efficacy in children and adolescents have not been established.

These instructions define the standardized, procedural steps for using Diamicron LM.

The research on Diamicron LM (Gliclazide Modified Release) is anchored in a foundation of clinical trials and systematic reviews, primarily focusing on its study in Type 2 Diabetes Mellitus. This overview describes the structures of these studies, what types of patient outcomes were examined, and where research remains uncertain.

---

Evidence for use in Type 2 Diabetes Mellitus

Research exploring the use of Diamicron LM begins with studies conducted in adults with Type 2 Diabetes Mellitus. These trials, often Randomized Controlled Trials (RCTs), examined changes in blood glucose concentrations, primarily focusing on the level of Glycated Hemoglobin (HbA1c), which is a key biomarker for glucose status. Findings describe patterns observed in the studies over short- to medium-term follow-up intervals. Initial research also explored the effects of Diamicron LM in patients who had previously managed their condition solely through diet and lifestyle changes.

---

Long-Term Data on Vascular Outcomes and Durability

The research base includes large-scale, international RCTs that provided extended follow-up data (up to five years). These studies evaluated outcomes related to the progression of diabetes complications. They explored the differences in the occurrence of major vascular events between intensive and standard control groups, with Gliclazide Modified Release being a core component of the intensive strategy. Studies reported patterns related to the overall combined vascular event rate and patterns observed in outcomes linked to new or worsening kidney disease (nephropathy). Findings on macrovascular events, such as heart attack and stroke, were not definitive between the two groups.

---

Evidence in Specific Patient Groups

Research has explored the use of Diamicron LM in certain specific patient sub-groups. Studies monitoring the use in older adults (aged ge 60 years) were conducted, where HbA1c status was evaluated. Research also explored its use in patients identified as having impaired renal function (chronic kidney disease). Patients considered to be at high cardiovascular risk were routinely included in the large long-term trials.

---

Research Landscape and Limitations

The overall evidence landscape for Diamicron LM includes data from large-scale trials, yet certain limitations apply, particularly in comparative research. The quality of evidence varies across studies, especially for head-to-head comparative RCTs against some of the other available oral antidiabetic agents. Research findings describe group patterns and do not determine whether an individual will respond similarly. Long-term data providing comprehensive insight into the most frail and medically complex elderly sub-groups remains limited due to typical trial exclusion criteria.

Key Studies & References Type 2 diabetes in adults: management (NICE Guideline NG28)

Common questions about Diamicron LM (FAQ)

---

Q: How long does it take for Diamicron LM to start working?

Regulatory documents describe the way the active ingredient, Gliclazide, is released into the body. The modified-release formulation is designed to release the medicine gradually, reaching a plateau phase (a stable concentration) typically maintained between the sixth and twelfth hour after administration. This controlled-release design is intended to help provide effective drug levels over a 24-hour period with once-daily dosing.

---

Q: How often should my doctor check my HbA1 c while on this medication?

Official guidance recognizes the use of the Glycated Haemoglobin ( HbA1 c) test to assess how blood sugar is controlled over time. While the drug label doesn't specify an exact patient monitoring frequency, clinical guidance often suggests that HbA1 c status may be reviewed within a three to six-month interval for patients on stable therapy.

---

Q: Does Diamicron LM interact with grapefruit juice or other foods?

Official product information provides specific details about interactions with other medicines, and particularly notes that alcohol has been documented to potentiate the blood sugar-lowering effect and is generally advised against in the product label. However, the regulatory documents do not explicitly list or mention any specific interaction warnings regarding grapefruit juice or other common foods.

---

Q: Can I use Diamicron LM if I am trying to get pregnant?

If you are planning to become pregnant, product information indicates that a discussion with a healthcare professional is necessary regarding this matter. The medication is not recommended during pregnancy, and regulatory information notes that insulin therapy is often required if pregnancy is planned or confirmed.

---

Q: What are the names of the inactive ingredients (excipients) in the tablet?

The tablet is made up of the active ingredient, Gliclazide, and several non-medicinal ingredients (excipients) that help form the modified-release tablet. According to the official regulatory list, these typically include compounds such as Calcium hydrogen phosphate, Maltodextrin, Hypromellose, Magnesium stearate, and colloidal anhydrous silica.

---

Q: What are the physical characteristics of the tablet (color, shape, engraving)?

According to the official pharmaceutical form description, the tablet is typically a white, oblong or circular shape. It often features flat bevelled edges and may be marked or engraved on one side with a product identifier to help distinguish the strength or the medicine name.

---

Q: What is the exact chemical structure or molecular formula of Gliclazide?

The active ingredient, Gliclazide, is chemically classified as a sulfonylurea derivative. Its molecular formula, as stated in official regulatory and chemical information, is C15 H21 N3 O3 S.

How to Store and Dispose of Diamicron LM?

The storage and disposal instructions for Diamicron LM (Gliclazide Modified-Release) are defined by the medicine's official regulatory labeling.

Storage Scope	Official Requirement
Temperature	Store in a cool, dry place below 30 C or at room temperature; the product label may state no special storage conditions are required.
Packaging	Keep the tablets in the original pack (blister); stability is compromised if the tablets are removed from the packaging prematurely.
Safety	Keep out of the sight and reach of children.
Stability	Do not use the tablets after the expiry date printed on the carton.
Disposal	Return any leftover tablets to a pharmacist for disposal or discard the product in accordance with local requirements. The medicine must not be disposed of via household rubbish or wastewater.